These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

726 related articles for article (PubMed ID: 1356869)

  • 1. Acid suppression in the long-term treatment of peptic stricture and Barrett's oesophagus.
    Lundell L
    Digestion; 1992; 51 Suppl 1():49-58. PubMed ID: 1356869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study.
    Peters FT; Ganesh S; Kuipers EJ; Sluiter WJ; Klinkenberg-Knol EC; Lamers CB; Kleibeuker JH
    Gut; 1999 Oct; 45(4):489-94. PubMed ID: 10486353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease.
    Lambert R
    Aliment Pharmacol Ther; 1997 Aug; 11(4):651-62. PubMed ID: 9305472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of predictors of normalization of oesophageal acid exposure in Barrett's oesophagus.
    Wani S; Sampliner RE; Weston AP; Mathur S; Hall M; Higbee A; Sharma P
    Aliment Pharmacol Ther; 2005 Oct; 22(7):627-33. PubMed ID: 16181302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lansoprazole heals erosive reflux oesophagitis in patients with Barrett's oesophagus.
    Sontag SJ; Schnell TG; Chejfec G; Kurucar C; Karpf J; Levine G
    Aliment Pharmacol Ther; 1997 Feb; 11(1):147-56. PubMed ID: 9042987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in Barrett's oesophagus.
    Marshall RE; Anggiansah A; Manifold DK; Owen WA; Owen WJ
    Gut; 1998 Nov; 43(5):603-6. PubMed ID: 9824338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent acid reflux and symptoms in patients with Barrett's oesophagus on proton-pump inhibitor therapy.
    Basu KK; Bale R; West KP; de Caestecker JS
    Eur J Gastroenterol Hepatol; 2002 Nov; 14(11):1187-92. PubMed ID: 12439112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
    Todd JA; Basu KK; de Caestecker JS
    Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.
    Ortiz A; Martínez de Haro LF; Parrilla P; Molina J; Bermejo J; Munitiz V
    Br J Surg; 1999 Nov; 86(11):1472-4. PubMed ID: 10583299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term continuous omeprazole treatment of patients with Barrett's oesophagus.
    Neumann CS; Iqbal TH; Cooper BT
    Aliment Pharmacol Ther; 1995 Aug; 9(4):451-4. PubMed ID: 8527623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and treatment of Barrett's oesophagus. A general survey.
    Petrakis IE; Sciacca V; Iascone C
    Acta Chir Belg; 2001; 101(2):53-8. PubMed ID: 11396051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study.
    Moghissi K; Sharpe DA; Pender D
    Eur J Cardiothorac Surg; 1993; 7(3):126-31. PubMed ID: 8461144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans.
    Tan MC; El-Serag HB; Yu X; Thrift AP
    Aliment Pharmacol Ther; 2018 Aug; 48(4):469-477. PubMed ID: 29956826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's oesophagus: a clinical study of 52 patients.
    Cooper BT; Barbezat GO
    Q J Med; 1987 Feb; 62(238):97-108. PubMed ID: 3498962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reflux strictures of the oesophagus in children: personal experience with preoperative dilatation followed by anterior funduplication.
    Briganti V; Oriolo L; Calisti A
    Pediatr Surg Int; 2003 Sep; 19(7):544-7. PubMed ID: 12961093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximal acid reflux control for Barrett's oesophagus: feasible and effective.
    Srinivasan R; Katz PO; Ramakrishnan A; Katzka DA; Vela MF; Castell DO
    Aliment Pharmacol Ther; 2001 Apr; 15(4):519-24. PubMed ID: 11284781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression.
    Fitzgerald RC; Lascar R; Triadafilopoulos G
    Aliment Pharmacol Ther; 2001 Mar; 15(3):269-76. PubMed ID: 11207503
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 37.